<div id="readability-page-1"><h3>Claim 30% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>An announcement from Sino Biopharmaceutical ( (HK:1177) ) is now available. Sino Biopharmaceutical announced that its subsidiary LaNova Medicines presented preliminary clinical data at a major cancer research conference for MK-2010/LM-299, an investigational PD-1/VEGF tetravalent bispecific antibody for advanced solid tumors. The candidate, licensed globally to Merck for development and commercialization, is designed to combine immune checkpoint inhibition with anti-angiogenic effects in a single IgG-VHH fusion molecule. In a Phase 1/2 study involving 112 heavily pretreated patients, MK-2010/LM-299 showed a manageable safety profile with no treatment-related deaths and limited high-grade toxicities, while VEGF-related side effects were generally controllable. Early efficacy signals in first-line non-small cell lung cancer were notable, with an overall response rate of 55% at the 20 mg/kg dosing level and 44% at 30 mg/kg, supporting continued development of the drug as both a monotherapy and in combination regimens. These results highlight Sino Biopharmaceutical’s growing role in innovative oncology biologics and underscore the strategic value of its alliance with Merck in advancing MK-2010/LM-299 globally. Positive early data may enhance the company’s scientific standing, potentially strengthen its oncology pipeline positioning and offer future upside for patients and stakeholders if further trials confirm safety and efficacy. The most recent analyst rating on (HK:1177) stock is a Buy with a HK$8.70 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page. More about Sino Biopharmaceutical Sino Biopharmaceutical Limited is a Hong Kong-listed pharmaceutical company focused on the research, development, manufacturing and commercialization of innovative medicines, particularly in oncology and other therapeutic areas. Through its wholly owned subsidiary LaNova Medicines, the Group advances cutting-edge biologics, including bispecific antibodies targeting major cancer pathways, to strengthen its presence in the global biopharmaceutical market. The company leverages partnerships with multinational pharmaceutical firms to expand development and commercialization of its pipeline globally. Its strategy emphasizes clinical innovation, international collaboration and participation in major scientific forums to enhance its competitiveness and visibility in oncology drug development. YTD Price Performance: -0.16% Average Trading Volume: 69,721,589 Technical Sentiment Signal: Buy Current Market Cap: HK$110.3B Learn more about 1177 stock on TipRanks’ Stock Analysis page.</div>

01177

08037

512010

Sino Biopharmaceutical's subsidiary LaNova Medicines presented promising early clinical data for MK-2010/LM-299, a PD-1/VEGF bispecific cancer drug licensed to Merck. In a Phase 1/2 study with 112 patients, the drug demonstrated a manageable safety profile and notable efficacy signals, particularly in non-small cell lung cancer, with an overall response rate of 55% at 20 mg/kg. This development enhances Sino Biopharmaceutical's position in oncology and underscores the strategic partnership with Merck. Analysts rate the stock as a Buy with a target price of HK$8.70.

Tip Ranks

SBP GROUP

CH BIOTECH SER

E Fund CSI 300 Health Care ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

China Southern Hang Seng Biotech ETF(QDII)

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Guotai SSE STAR Brand Name Drug ETF

ChinaAMC SSE Health Care ETF Initiating Fund

ChinaAMC CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

Yinhua CSI Innovative Drugs Industry ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Penghua CSI HK Connect Health Care Composite ETF

ChinaAMC SSE STAR Biology and Medicine ETF

China Universal 800 Health Care ETF

Bosera Hang Seng Health Care ETF(QDII)

Minsheng Royal CSI Biotechnology Theme ETF

Dacheng CSI All Share Health Care Equipment and Services ETF

Merck

Sino Biopharm Reports Promising Early Data for PD-1/VEGF Bispecific Cancer Drug Licensed to Merck